Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Status:
Completed
Trial end date:
2021-07-14
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of H.P. Acthar gel for treating the cutaneous
manifestations in patients with refractory classic dermatomyositis, juvenile dermatomyositis,
and amyopathic dermatomyositis. Our hypothesis is that H.P. Acthar gel will be both safe and
effective for such patients.